Literature DB >> 18602856

The biology and pathobiology of LRRK2: implications for Parkinson's disease.

Darren J Moore1.   

Abstract

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are an important cause of late-onset, familial and sporadic Parkinson's disease. LRRK2 is a large unique protein containing both GTPase and kinase enzymatic domains together with multiple protein-protein interaction domains. LRRK2 initially appears to function as a GTPase-regulated protein kinase. The majority of pathogenic mutations lead to enhanced kinase activity of LRRK2. Disease-associated mutations in LRRK2 also promote the formation of cytoplasmic inclusions and induce neuronal toxicity in cultured cells in a kinase-dependent manner. These and other important aspects of LRRK2 biology and pathophysiology are discussed in detail in this review.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18602856     DOI: 10.1016/j.parkreldis.2008.04.010

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  14 in total

Review 1.  Mechanisms of LRRK2-mediated neurodegeneration.

Authors:  Elpida Tsika; Darren J Moore
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

Review 2.  Mitochondrial dysfunction in genetic animal models of Parkinson's disease.

Authors:  Alzbeta Trancikova; Elpida Tsika; Darren J Moore
Journal:  Antioxid Redox Signal       Date:  2011-10-04       Impact factor: 8.401

Review 3.  Gene therapy in Parkinson's disease: rationale and current status.

Authors:  Li Rebekah Feng; Kathleen A Maguire-Zeiss
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

4.  Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.

Authors:  João Paulo L Daher; Olga Pletnikova; Saskia Biskup; Alessandra Musso; Sandra Gellhaar; Dagmar Galter; Juan C Troncoso; Michael K Lee; Ted M Dawson; Valina L Dawson; Darren J Moore
Journal:  Hum Mol Genet       Date:  2012-02-21       Impact factor: 6.150

5.  LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease.

Authors:  Z Gan-Or; A Bar-Shira; A Mirelman; T Gurevich; M Kedmi; N Giladi; A Orr-Urtreger
Journal:  Neurogenetics       Date:  2009-05-21       Impact factor: 2.660

6.  Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease.

Authors:  Shinji Higashi; Darren J Moore; Ryoko Yamamoto; Michiko Minegishi; Kiyoshi Sato; Takashi Togo; Omi Katsuse; Hirotake Uchikado; Yoshiko Furukawa; Hiroaki Hino; Kenji Kosaka; Piers C Emson; Keiji Wada; Valina L Dawson; Ted M Dawson; Heii Arai; Eizo Iseki
Journal:  J Neuropathol Exp Neurol       Date:  2009-09       Impact factor: 3.685

Review 7.  Dopamine release in the basal ganglia.

Authors:  M E Rice; J C Patel; S J Cragg
Journal:  Neuroscience       Date:  2011-09-14       Impact factor: 3.590

8.  Sequences located within the N-terminus of the PD-linked LRRK2 lead to increased aggregation and attenuation of 6-hydroxydopamine-induced cell death.

Authors:  Neeraj Pandey; Mark T Fahey; Yuh-Jiin I Jong; Karen L O'Malley
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

9.  Dopaminergic expression of the Parkinsonian gene LRRK2-G2019S leads to non-autonomous visual neurodegeneration, accelerated by increased neural demands for energy.

Authors:  Samantha Hindle; Farinaz Afsari; Meg Stark; C Adam Middleton; Gareth J O Evans; Sean T Sweeney; Christopher J H Elliott
Journal:  Hum Mol Genet       Date:  2013-02-07       Impact factor: 6.150

10.  Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways.

Authors:  Lauran Reyniers; Maria Grazia Del Giudice; Laura Civiero; Elisa Belluzzi; Evy Lobbestael; Alexandra Beilina; Giorgio Arrigoni; Rita Derua; Etienne Waelkens; Yan Li; Claudia Crosio; Ciro Iaccarino; Mark R Cookson; Veerle Baekelandt; Elisa Greggio; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2014-07-14       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.